Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Antibe’s revolutionary pain drug is entering Phase 3 trials
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1164)
•••
Comment by Pandoraon Nov 30, 2020 10:09pm
261 Views
Post# 32006845

RE:Antibe’s revolutionary pain drug is entering Phase 3 trials

RE:Antibe’s revolutionary pain drug is entering Phase 3 trials
UVPGuy wrote: This morning, BNN Bloomberg posted an article about Antibe Therapeutics (TSX: ATE | OTCQB: ATBPF) and their revolutionary pain drug entering Phase 3 trials. The company is a clinical-stage biotechnology company currently leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation.

“We’ve made tremendous progress this quarter in preparing our lead drug for Phase 3 trials and partnering. We are getting closer to the start of our Phase 3 program, with a total of eight Phase 3-enabling studies now running in parallel.” - Dan Legault, CEO 

Read the full article here: https://www.bnnbloomberg.ca/investors-take-note-antibe-s-revolutionary-pain-drug-is-entering-phase-3-trials-1.1527633

Learn more about Antibe Therapeutics here: https://antibethera.com/


Just a question from curiosity - June 1 & 2 they announced top line results for Phase llB study. Why does it take 8 months to then get started on Phase lll?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities